Drug intelligence / Profile preview

IRZ-01

Development stage: Preclinical
Lead developer: Irazú Oncology
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

IRZ-01 is an investigational cancer immunotherapy being developed by Irazu Oncology. It is a protein-based cancer vaccine designed to target two tumor-associated antigens, mucin 1 (MUC1) and carcinoembryonic antigen (CEA), both of which are commonly overexpressed in various solid tumors. The drug acts as an immunostimulant, aiming to induce or enhance the immune system's response against cancer cells expressing these antigens. As of March 2025, development remains in the preclinical stage for the treatment of solid tumors[1][2].

Other names: IRZ 01IRZ01IRZ-01

Targets

MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on IRZ-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IRZ-01.

Explore the full profile